BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, Sofocleous CT, Sze DY; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2012;23:287-294. [PMID: 22284821 DOI: 10.1016/j.jvir.2011.11.029] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 12.0] [Reference Citation Analysis]
2 Huo T, Lin H, Hsia C, Wu J, Lee P, Chi C, Lee S. The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. Am J Gastroenterology 2007;102:1920-30. [DOI: 10.1111/j.1572-0241.2007.01370.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
3 Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101:975-982. [PMID: 16573785 DOI: 10.1111/j.1572-0241.2006.00462.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
4 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
6 Huo TI, Huang YH, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scand J Gastroenterol 2007;42:485-92. [PMID: 17454859 DOI: 10.1080/00365520600931402] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
7 Huo TI, Wu JC, Huang YH, Chiang JH, Lee PC, Chang FY, Lee SD. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther. 2004;19:999-1007. [PMID: 15113367 DOI: 10.1111/j.1365-2036.2004.01936.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
8 Asrani SK, Kim WR. Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. Curr Opin Gastroenterol 2010;26:209-13. [PMID: 20224394 DOI: 10.1097/MOG.0b013e32833867d8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
9 Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247] [Cited by in Crossref: 164] [Cited by in F6Publishing: 145] [Article Influence: 18.2] [Reference Citation Analysis]
10 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
12 Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Dig Dis Sci. 2020;65:658-667. [PMID: 31659612 DOI: 10.1007/s10620-019-05813-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352-361. [PMID: 18008352 DOI: 10.1002/cncr.23185] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
15 Huo T, Wu J, Lin H, Lee F, Hou M, Lee P, Chang F, Lee S. Evaluation of the increase in model for end-stage liver disease (ΔMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child–Turcotte–Pugh score. Journal of Hepatology 2005;42:826-32. [DOI: 10.1016/j.jhep.2005.01.019] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 6.4] [Reference Citation Analysis]
16 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
17 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
18 Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan DK, Vedantham S, Miller DL, Brountzos EN, Grassi CJ, Towbin RB; SIR Standards of Practice Committee, Angle JF, Balter S, Clark TW, Cole PE, Drescher P, Freeman NJ, Georgia JD, Haskal Z, Hovsepian DM, Kilnani NM, Kundu S, Malloy PC, Martin LG, McGraw JK, Meranze SG, Meyers PM, Millward SF, Murphy K, Neithamer CD Jr, Omary RA, Patel NH, Roberts AC, Schwartzberg MS, Siskin GP, Smouse HR, Swan TL, Thorpe PE, Vesely TM, Wagner LK, Wiechmann BN, Bakal CW, Lewis CA, Nemcek AA Jr, Rholl KS. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2009;20:S219-S226, S226.e1-S226.10. [PMID: 19560002 DOI: 10.1016/j.jvir.2009.04.033] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
19 Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD. Different model for end-stage liver disease score block distributions may have a variable ability for outcome prediction. Transplantation. 2005;80:1414-1418. [PMID: 16340784 DOI: 10.1097/01.tp.0000181164.19658.7a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
20 Brennan IM, Faintuch S, Ahmed M. Preparation for Percutaneous Ablation Procedures. Techniques in Vascular and Interventional Radiology 2013;16:209-18. [DOI: 10.1053/j.tvir.2013.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Huo TI, Lin HC, Wu JC, Hou MC, Lee FY, Lee PC, Chang FY, Lee SD. Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin Transplant. 2006;20:188-194. [PMID: 16640525 DOI: 10.1111/j.1399-0012.2005.00463.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
22 Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805. [PMID: 17326206 DOI: 10.1002/hep.21563] [Cited by in Crossref: 914] [Cited by in F6Publishing: 796] [Article Influence: 60.9] [Reference Citation Analysis]
23 Befeler AS. Chemoembolization and bland embolization: a critical appraisal. Clin Liver Dis 2005;9:287-300, vii. [PMID: 15831274 DOI: 10.1016/j.cld.2004.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
24 Huo T, Wu J, Lin H, Lee F, Hou M, Huang Y, Lee P, Chang F, Lee S. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 2004;10:1507-13. [DOI: 10.1002/lt.20310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
25 Huo TI, Lin HC, Lee SD. Model for end-stage liver disease and organ allocation in liver transplantation: where are we and where should we go? J Chin Med Assoc. 2006;69:193-198. [PMID: 16835979 DOI: 10.1016/S1726-4901(09)70217-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis. 2008;40:882-889. [PMID: 18339595 DOI: 10.1016/j.dld.2008.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
27 Lee HA, Jung JY, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Um SH, Seo YS. Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis. Gut Liver 2021;15:599-605. [PMID: 33293481 DOI: 10.5009/gnl20171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl. 2006;12:65-71. [PMID: 16382473 DOI: 10.1002/lt.20560] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
29 Limquiaco JL, Wong GL, Wong VW, Lai PB, Chan HL. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:63-69. [PMID: 19054256 DOI: 10.1111/j.1440-1746.2008.05701.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
31 Huo T, Lin H, Huang Y, Wu J, Chiang J, Lee P, Lee S. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006;107:141-8. [DOI: 10.1002/cncr.21972] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
32 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Wang YL, Li MH, Cheng YS, Shi HB, Fan HL. Influential factors and formation of extrahepatic collateral artery in unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11(17): 2637-2642 [PMID: 15849825 DOI: 10.3748/wjg.v11.i17.2637] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
34 Giannini EG, Testa R. Reply to Farina ti et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green. J Intern Med 2004;256:531-531. [DOI: 10.1111/j.1365-2796.2004.01408.x] [Reference Citation Analysis]
35 Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. Hepatol Res. 2010;40:1082-1091. [PMID: 20880059 DOI: 10.1111/j.1872-034x.2010.00714.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19:105-115. [PMID: 23837134 DOI: 10.3350/cmh.2013.19.2.105] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
37 Brown DB, Fundakowski CE, Lisker-Melman M, Crippin JS, Pilgram TK, Chapman W, Darcy MD. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209-1218. [PMID: 15525739 DOI: 10.1097/01.rvi.0000128123.04554.c1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
38 Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan D, Vedantham S, Miller DL, Brountzos EN, Grassi CJ, Towbin RB. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006;17:225-32. [PMID: 16517768 DOI: 10.1097/01.RVI.0000195330.47954.48] [Cited by in Crossref: 80] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
39 Huo TI, Lee PC, Huang YH, Wu JC, Lin HC, Chiang JH, Lee SD. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol 2006;40:543-50. [PMID: 16825938 DOI: 10.1097/00004836-200607000-00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
40 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
41 Georgiades CS, Liapi E, Frangakis C, Park JU, Kim HW, Hong K, Geschwind JF. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006;17:1619-24. [PMID: 17057003 DOI: 10.1097/01.RVI.0000236608.91960.34] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]